<DOC>
	<DOC>NCT02397694</DOC>
	<brief_summary>This study will evaluate the efficacy, safety and tolerability of bictegravir (BIC) + emtricitabine/tenofovir alafenamide (FTC/TAF) fixed dose combination (FDC) versus dolutegravir (DTG) + FTC/TAF in HIV-1 Infected, antiretroviral treatment-naive adults. This study will also evaluate the pharmacokinetic (PK) profile of BIC, FTC and TAF.</brief_summary>
	<brief_title>Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Key Antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent) Plasma HIV1 RNA levels ≥ 1,000 copies/mL at screening Screening genotype report provided by Gilead Sciences must show sensitivity to tenofovir (TFV) and FTC Adequate renal function as measured by estimated glomerular filtration rate ≥ 70 mL/min according to the CockcroftGault formula CD4+ cell count &gt; 200 cells/µL at screening Key A new AIDSdefining condition diagnosed within the 30 days prior to screening as defined in the study protocol Prior use of antiretrovirals in the setting of preexposure prophylaxis (PrEP) or post exposure prophylaxis (PEP) Chronic hepatitis B virus (HBV) infection Hepatitis C infection (Individuals who are hepatitis C virus (HCV) Ab positive, but have a documented negative HCV RNA, are eligible) Active, serious infections (other than HIV1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline Participation in any other clinical trial without prior approval from the sponsor is prohibited while participating in this trial Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Adult</keyword>
	<keyword>HIV</keyword>
	<keyword>naive</keyword>
</DOC>